Affordable Access

N-Acetyltransferase (NAT) 2 acetylator status and age of tumour onset in patients with sporadic and familial, microsatellite stable (MSS) colorectal cancer.

Authors
  • Pistorius, Steffen
  • Goergens, Heike
  • Engel, Christoph
  • Plaschke, Jens
  • Krueger, Stefan
  • Hoehl, Ruth
  • Saeger, Hans-Detlev
  • Schackert, Hans K
Type
Published Article
Journal
International journal of colorectal disease
Publication Date
Feb 01, 2007
Volume
22
Issue
2
Pages
137–143
Identifiers
PMID: 16896994
Source
Medline
License
Unknown

Abstract

We did not observe any significant difference in the NAT2 acetylator status frequency between patients in both groups and 100 healthy controls (P=0.486). Regardless of a younger median age of tumour onset (AO) of 41 years in group 2 patients compared to 64 years in group 1 patients, no significant difference in AO was found between RA and SA status patients in both groups. The median AO in group 1 was 65 years in patients with RA and 63 years with SA status (P=0.065). The median AO in group 2 was 40 years in patients with RA and 42 years with SA status (P=0.814). Multivariate Cox regression analysis revealed that neither the NAT2 acetylator status (P=0.064 and 0.810, respectively) nor the gender (P=0.165 and 0.918, respectively) was a risk factor for the AO in both groups. These data do not support the hypothesis that the NAT2 acetylatorship acts as a modifying factor on the AO in sporadic and familial, microsatellite stable CRC.

Report this publication

Statistics

Seen <100 times